Istari is advancing clinical research across multiple solid tumor types with lerapolturev (formerly PVSRIPO), the only investigational immunotherapy based on the Sabin oral poliovirus vaccine. Lerapolturev leverages multiple, unique mechanisms of action to activate a systemic antitumor response to fight cancer. Lerapolturev has been administered to more than 200 patients and is currently the subject of multiple ongoing phase 2 trials in 6 potential solid tumor indications.
Lerapolturev has been designated an Orphan Drug and granted Breakthrough Therapy Designation for recurrent glioblastoma (rGBM) by the FDA. Lerapolturev has also been designated an Orphan Drug in advanced melanoma (stage IIb-IV) and granted Fast Track status for patients with advanced melanoma who have disease progression after anti–PD-1/L1 therapy.
*Patients will be treated with lerapolturev monotherapy during phase 1 and lerapolturev in combination with anti–PD-1/L1 during phase 2.